In summary, many of the most promising preclinical data on novel approaches to improve antiepileptic drug delivery are aimed at either disrupting or bypassing the BBB, including Trojan horse technology that would allow targeting of large (and water insoluble) molecules through the BBB to epileptic brain regions responsible for seizure generation. The most important aspect is that such novel delivery approaches will allow clinical testing for antiepileptic activity of large molecules that were previously barred from development of epilepsy drugs. There may be a whole new world of effective epilepsy drugs that were excluded from experimental, and clinical evaluation simply because they could not cross the BBB. Researchers and practitioners in the field eagerly await the results—with cautious optimism and with high hopes.Ultimately, our best chance for effectively treating and preventing epilepsy will involve therapies that, on the one hand, safely and specifically regulate seizure generation and, on the other hand, enhance the safety and tolerability by avoiding systemic toxicity. Once clinical trials of new delivery techniques have been conducted, the hope is that we will soon have novel epilepsy therapeutics that successfully and safely stop seizures in more patients than is possible today.

中文翻译：

---

评论：抗癫痫药物的新型给药方法：希望和障碍。

总之，许多关于改善抗癫痫药物递送的新方法的最有希望的临床前数据旨在破坏或绕过 BBB，包括特洛伊木马技术，该技术允许通过 BBB 将大分子（和水不溶性）靶向至癫痫脑负责癫痫发作的区域。最重要的方面是，这种新型递送方法将允许对以前被禁止开发癫痫药物的大分子的抗癫痫活性进行临床测试。可能会有一个全新的有效癫痫药物世界，这些药物仅仅因为无法通过 BBB 而被排除在实验和临床评估之外。该领域的研究人员和从业人员怀着谨慎的乐观和寄予厚望的态度，热切地等待着结果。最终，我们有效治疗和预防癫痫的最佳机会将涉及治疗，一方面，安全和特异性地调节癫痫发作的产​​生，另一方面，通过避免全身毒性来提高安全性和耐受性。一旦进行了新递送技术的临床试验，希望我们很快就会有新的癫痫治疗方法，能够成功、安全地阻止比今天更多的患者癫痫发作。